200 related articles for article (PubMed ID: 25116971)
1. Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both.
Wu JJ; Poon KY
J Drugs Dermatol; 2014 Aug; 13(8):932-4. PubMed ID: 25116971
[TBL] [Abstract][Full Text] [Related]
2. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
3. Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients?
Armstrong AW
JAMA; 2013 May; 309(19):2043-4. PubMed ID: 23677316
[TBL] [Abstract][Full Text] [Related]
4. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Channual JC; Shen AY
Arch Dermatol; 2012 Nov; 148(11):1244-50. PubMed ID: 22911151
[TBL] [Abstract][Full Text] [Related]
5. Risk of Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis: A Nationwide Cohort Study.
Egeberg A; Thyssen JP; Jensen P; Gislason GH; Skov L
Acta Derm Venereol; 2017 Jul; 97(7):819-824. PubMed ID: 28350413
[TBL] [Abstract][Full Text] [Related]
6. The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study.
Shaaban D; Al-Mutairi N
J Dermatolog Treat; 2018 Feb; 29(1):3-7. PubMed ID: 27881030
[TBL] [Abstract][Full Text] [Related]
7. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis.
Wu JJ; Joshi AA; Reddy SP; Batech M; Egeberg A; Ahlehoff O; Mehta NN
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1320-1326. PubMed ID: 29573294
[TBL] [Abstract][Full Text] [Related]
9. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
10. Risk of myocardial infarction in canadian patients with psoriasis: a retrospective cohort study.
Levesque A; Lachaine J; Bissonnette R
J Cutan Med Surg; 2013; 17(6):398-403. PubMed ID: 24138976
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
12. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
[TBL] [Abstract][Full Text] [Related]
13. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study.
Chen YJ; Chang YT; Shen JL; Chen TT; Wang CB; Chen CM; Wu CY
Arthritis Rheum; 2012 Jun; 64(6):1879-87. PubMed ID: 22161801
[TBL] [Abstract][Full Text] [Related]
14. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study.
Abuabara K; Lee H; Kimball AB
Br J Dermatol; 2011 Nov; 165(5):1066-73. PubMed ID: 21777216
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
[TBL] [Abstract][Full Text] [Related]
16. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
Cho YT; Chen CH; Chiu HY; Tsai TF
J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
[TBL] [Abstract][Full Text] [Related]
17. Association of gender, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY
J Am Acad Dermatol; 2013 Oct; 69(4):650-1. PubMed ID: 24034374
[No Abstract] [Full Text] [Related]
18. Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders.
Hession MT; Gottlieb AB
J Dermatolog Treat; 2011 Apr; 22(2):90-101. PubMed ID: 20673155
[TBL] [Abstract][Full Text] [Related]
19. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
Krueger G; Callis K
Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
[TBL] [Abstract][Full Text] [Related]
20. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?
Cuchacovich R; Espinoza CG; Virk Z; Espinoza LR
J Clin Rheumatol; 2008 Dec; 14(6):353-6. PubMed ID: 19033869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
